235 related articles for article (PubMed ID: 29855035)
1. Monoclonal antibody-mediated killing of tumour cells by neutrophils.
Heemskerk N; van Egmond M
Eur J Clin Invest; 2018 Nov; 48 Suppl 2(Suppl Suppl 2):e12962. PubMed ID: 29855035
[TBL] [Abstract][Full Text] [Related]
2. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
3. Neutrophils as effector cells for antibody-based immunotherapy of cancer.
van Egmond M; Bakema JE
Semin Cancer Biol; 2013 Jun; 23(3):190-9. PubMed ID: 23287459
[TBL] [Abstract][Full Text] [Related]
4. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
5. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T
Front Immunol; 2019; 10():704. PubMed ID: 31031746
[TBL] [Abstract][Full Text] [Related]
6. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin A: magic bullet or Trojan horse?
Heineke MH; van Egmond M
Eur J Clin Invest; 2017 Feb; 47(2):184-192. PubMed ID: 28024097
[TBL] [Abstract][Full Text] [Related]
8. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
9. Neutrophils in antibody-based immunotherapy of cancer.
van Egmond M
Expert Opin Biol Ther; 2008 Jan; 8(1):83-94. PubMed ID: 18081538
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
Stadick H; Stockmeyer B; Kühn R; Schrott KM; Kalden JR; Glennie MJ; van de Winkel JG; Gramatzki M; Valerius T; Elsässer D
J Urol; 2002 Feb; 167(2 Pt 1):707-12. PubMed ID: 11792958
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
12. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
14. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic exploitation of neutrophils to fight cancer.
Gruijs M; Sewnath CAN; van Egmond M
Semin Immunol; 2021 Oct; 57():101581. PubMed ID: 34922817
[TBL] [Abstract][Full Text] [Related]
17. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
Heemskerk N; Gruijs M; Temming AR; Heineke MH; Gout DY; Hellingman T; Tuk CW; Winter PJ; Lissenberg-Thunnissen S; Bentlage AE; de Donatis M; Bögels M; Rösner T; Valerius T; Bakema JE; Vidarsson G; van Egmond M
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33561014
[TBL] [Abstract][Full Text] [Related]
18. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
19. Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc gamma -receptors.
Ottonello L; Epstein AL; Mancini M; Tortolina G; Dapino P; Dallegri F
Br J Cancer; 2001 Aug; 85(3):463-9. PubMed ID: 11487281
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
